DK1471871T3 - Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin - Google Patents

Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin

Info

Publication number
DK1471871T3
DK1471871T3 DK02724904T DK02724904T DK1471871T3 DK 1471871 T3 DK1471871 T3 DK 1471871T3 DK 02724904 T DK02724904 T DK 02724904T DK 02724904 T DK02724904 T DK 02724904T DK 1471871 T3 DK1471871 T3 DK 1471871T3
Authority
DK
Denmark
Prior art keywords
erythropoietin
treatment
neurological dysfunction
dysfunction including
fructopyranose sulfamates
Prior art date
Application number
DK02724904T
Other languages
Danish (da)
English (en)
Inventor
Salaman Carlos Plata
Virginia Smith-Swintosky
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1471871T3 publication Critical patent/DK1471871T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK02724904T 2001-02-02 2002-01-24 Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin DK1471871T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26619401P 2001-02-02 2001-02-02
PCT/US2002/003096 WO2002064085A2 (en) 2001-02-02 2002-01-24 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

Publications (1)

Publication Number Publication Date
DK1471871T3 true DK1471871T3 (da) 2007-09-17

Family

ID=23013568

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02724904T DK1471871T3 (da) 2001-02-02 2002-01-24 Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin

Country Status (17)

Country Link
US (2) US6908902B2 (enExample)
EP (1) EP1471871B1 (enExample)
JP (1) JP2005501801A (enExample)
KR (1) KR100896971B1 (enExample)
AT (1) ATE361089T1 (enExample)
CA (1) CA2437333A1 (enExample)
CY (1) CY1106733T1 (enExample)
DE (1) DE60219961T8 (enExample)
DK (1) DK1471871T3 (enExample)
ES (1) ES2284858T3 (enExample)
MX (1) MXPA03006952A (enExample)
NO (1) NO20033440L (enExample)
NZ (1) NZ548578A (enExample)
PT (1) PT1471871E (enExample)
RU (1) RU2317086C2 (enExample)
WO (1) WO2002064085A2 (enExample)
ZA (1) ZA200306818B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
JP2005501801A (ja) * 2001-02-02 2005-01-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療
CA2459146A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
EP1535065A4 (en) * 2002-06-11 2007-07-11 Burnham Inst NEUROPROTECTOR SYNERGY OF ERYTHROPOIETIN AND INSULIN-LIKE GROWTH FACTOR
DE10226814A1 (de) * 2002-06-15 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
US20030235576A1 (en) * 2002-06-15 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of ischaemic conditions
ES2286453T3 (es) * 2002-09-17 2007-12-01 Motac Neuroscience Limited Tratamiento de la discinesia.
EP1815854A1 (en) * 2002-09-17 2007-08-08 Motac Neuroscience Limited Treatment of dyskenesia
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AT500929B1 (de) * 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
JPWO2007020922A1 (ja) * 2005-08-17 2009-02-26 創 戸苅 脳疾患の治療剤および予防剤
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2008022349A2 (en) * 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
CA2686816A1 (en) * 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
RU2335296C1 (ru) * 2007-06-26 2008-10-10 Сергей Марович Дудкин Фармацевтическая композиция для профилактики и лечения неврологических заболеваний
EP2997976A1 (en) * 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
EP2303309A2 (en) * 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
EP2785378B1 (en) 2011-12-02 2020-05-13 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN104220064B (zh) 2012-03-23 2017-10-10 中国人民解放军军事医学科学院毒物药物研究所 一种含辛弗林和托吡酯的联合产品
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
JPH09501418A (ja) 1993-07-19 1997-02-10 アムジエン・インコーポレーテツド エアゾル化タンパク質の安定化
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
PT736029E (pt) * 1993-12-23 2006-05-31 Ortho Mcneil Pharm Inc Sulfamatos de pseudofructopiranose anticonvulsivos
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
ES2273373T3 (es) 1996-08-02 2007-05-01 Ortho-Mcneil Pharmaceutical, Inc. Polipeptidos que tienen unido a su extremo n un unico polimero soluble al agua.
JP4541539B2 (ja) 1997-07-23 2010-09-08 ロシュ ダイアグノスティックス ゲーエムベーハー 内因性遺伝子活性化によるエリスロポエチンの製造
EP0902085B1 (en) 1997-09-01 2003-12-03 Aventis Pharma Deutschland GmbH Recombinant human erythropoietin with advantageous glycosylation profile
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
AU759467B2 (en) * 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
WO1999066054A2 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Erythropoietin analog-human serum albumin fusion protein
WO2000061138A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
KR101012932B1 (ko) * 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
CA2270795A1 (en) * 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
JP2005501801A (ja) * 2001-02-02 2005-01-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療

Also Published As

Publication number Publication date
WO2002064085A2 (en) 2002-08-22
ATE361089T1 (de) 2007-05-15
EP1471871A2 (en) 2004-11-03
EP1471871B1 (en) 2007-05-02
WO2002064085A3 (en) 2004-09-10
NO20033440L (no) 2003-09-29
EP1471871A4 (en) 2005-11-09
DE60219961T2 (de) 2008-01-17
KR100896971B1 (ko) 2009-05-14
KR20040011458A (ko) 2004-02-05
JP2005501801A (ja) 2005-01-20
ES2284858T3 (es) 2007-11-16
RU2317086C2 (ru) 2008-02-20
US20020169109A1 (en) 2002-11-14
MXPA03006952A (es) 2004-10-15
US6908902B2 (en) 2005-06-21
US20050261182A1 (en) 2005-11-24
ZA200306818B (en) 2005-02-23
DE60219961D1 (de) 2007-06-14
DE60219961T8 (de) 2008-04-17
CA2437333A1 (en) 2002-08-22
CY1106733T1 (el) 2012-05-23
PT1471871E (pt) 2007-06-05
RU2003124059A (ru) 2005-01-27
NO20033440D0 (no) 2003-08-01
NZ548578A (en) 2008-03-28

Similar Documents

Publication Publication Date Title
DK1471871T3 (da) Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin
MX231981B (es) Tratamiento de semillas con combinaciones de piretrinas/piretroides y clotianidina.
MXPA03003074A (es) Tratamiento para semilla con combinaciones de insecticidas
DK1660458T3 (da) 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
MX238203B (es) Tratamiento de semillas con combinaciones de piretrinas, piretroides y tlametoxam.
DK1392292T3 (da) Pyranoindazoler og deres anvendelse til behandling af glaukom
GB2394826A (en) Educational game
ITBO20000453A0 (it) Apparecchiatura e procedimento per la sterilizzazione del terreno .
DE60200302D1 (de) Laseraugenbehandlungseinrichtung
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
NO20023944L (no) Blanding og metoder for behandling av epilepsi
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
ATE333439T1 (de) Pflanzenkläranlage
BR0103928B1 (pt) equipamento para tratamento de efluentes e estação para tratamento de efluentes.
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
DK1500395T3 (da) Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser
FIU20010133U0 (fi) Jäteveden käsittelylaitteisto
DK1453783T3 (da) Substituerede arylcycloalkaner og deres anvendelse som anticancermidler
ATE374611T1 (de) Antitumor wirksame 2-alkoxyestradiolsulfamate
FR2825913B1 (fr) Stimulateur central hydro-dynamogene des membres inferieurs
DK1274700T3 (da) Dihydrobenzopyraner, dihydrobenzothiopyraner og tetrahydroquinoliner til behandling af COX-2-medierede lidelser
FI5282U1 (fi) Jäteveden puhdistamo
ES1050173Y (es) Medalla con calendario perfeccionada.